Reyon Pharmaceutical to Repurchase KRW 950 Million in Debt Before Maturity

Bitget2026/10/26 08:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Reyon Pharmaceutical will repurchase KRW 950 million of third-series convertible bonds before maturity on Oct. 26, 2026.
The purchase price totals KRW 1.05 billion, including principal and interest, funded with internal cash.
Outstanding principal will fall to KRW 83.95 billion; the bonds mature on Oct. 25, 2029.
The board will determine the repurchased bonds' subsequent treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261026000297), on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Reyon Pharmaceutical to Repurchase KRW 950 Million in Debt Before Maturity

You may also like

Crypto prices